Activation of cytotoxic and regulatory functions of NK cells by sindbis viral vectors

PLoS ONE

Volumn 6, Issue 6, 2011, Pages

  Granot, Tomer ^a   Venticinque, Lisa ^a   Tseng, Jen Chieh ^b   Meruelo, Daniel ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; GAMMA INTERFERON; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL FUNCTION; CELL SELECTION; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; LYMPHOCYTE ACTIVATION; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARY CARCINOMA; PERITONEUM MACROPHAGE; SINDBIS VIRUS; TUMOR GROWTH; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; ANIMAL; CELL COUNT; CELL TRANSFORMATION; CYTOLOGY; CYTOTOXICITY; GENE; GENE VECTOR; GENETICS; HAMSTER; IMMUNOLOGY; LACTOSE OPERON; METABOLISM; ONCOLYTIC VIROTHERAPY; PERITONEUM; PHYSIOLOGY; TRANSPLANTATION; TUMOR CELL LINE;

MUS; SINDBIS VIRUS;

ANIMALS; CELL COUNT; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; CRICETINAE; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GENES, MHC CLASS II; GENETIC VECTORS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-12; KILLER CELLS, NATURAL; LAC OPERON; MACROPHAGES, PERITONEAL; MICE; ONCOLYTIC VIROTHERAPY; PERITONEUM; SINDBIS VIRUS; UP-REGULATION;

EID: 79957932168     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0020598     Document Type: Article

References (50)

1. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE, (2007) Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-216.
2. Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, et al. (2009) The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 20: 1119-1132.
3. Bramson JL, Hitt M, Addison CL, Muller WJ, Gauldie J, et al. (1996) Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 7: 1995-2002.
4. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, et al. (1997) Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541-2548.
5. Hirasawa K, Nishikawa SG, Norman KL, Coffey MC, Thompson BG, et al. (2003) Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res 63: 348-353.
6. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM, (1991) Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252: 854-856.
7. Grote D, Russell SJ, Cornu TI, Cattaneo R, Vile R, et al. (2001) Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 97: 3746-3754.
8. Vaha-Koskela MJ, Kallio JP, Jansson LC, Heikkila JE, Zakhartchenko VA, et al. (2006) Oncolytic capacity of attenuated replicative semliki forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res 66: 7185-7194.
9. Toda M, Rabkin SD, Kojima H, Martuza RL, (1999) Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 10: 385-393.
10. Diaz RM, Galivo F, Kottke T, Wongthida P, Qiao J, et al. (2007) Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res 67: 2840-2848.
11. Hicks AM, Riedlinger G, Willingham MC, Alexander-Miller MA, Von Kap-Herr C, et al. (2006) Transferable anticancer innate immunity in spontaneous regression/complete resistance mice. Proc Natl Acad Sci U S A 103: 7753-7758.
12. Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S, (2008) Functions of natural killer cells. Nat Immunol 9: 503-510.
13. Wang KS, Kuhn RJ, Strauss EG, Ou S, Strauss JH, (1992) High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J Virol 66: 4992-5001.
14. Tseng JC, Zheng Y, Yee H, Levy DE, Meruelo D, (2007) Restricted tissue tropism and acquired resistance to Sindbis viral vector expression in the absence of innate and adaptive immunity. Gene Ther 14: 1166-1174.
15. Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S, (1993) Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol 67: 6439-6446.
16. Tseng JC, Zanzonico PB, Levin B, Finn R, Larson SM, et al. (2006) Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med 47: 1136-1143.
17. Tseng JC, Levin B, Hirano T, Yee H, Pampeno C, et al. (2002) In vivo antitumor activity of Sindbis viral vectors. J Natl Cancer Inst 94: 1790-1802.
18. Tseng JC, Levin B, Hurtado A, Yee H, Perez de Castro I, et al. (2004) Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 22: 70-77.
19. Tseng JC, Hurtado A, Yee H, Levin B, Boivin C, et al. (2004) Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res 64: 6684-6692.
20. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, et al. (1999) Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285: 727-729.
21. Kayagaki N, Yamaguchi N, Nakayama M, Takeda K, Akiba H, et al. (1999) Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J Immunol 163: 1906-1913.
22. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, et al. (1998) Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 188: 2375-2380.
23. Tanaka T, Kitamura F, Nagasaka Y, Kuida K, Suwa H, et al. (1993) Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice. J Exp Med 178: 1103-1107.
24. Habu S, Fukui H, Shimamura K, Kasai M, Nagai Y, et al. (1981) In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. J Immunol 127: 34-38.
25. Chan SH, Perussia B, Gupta JW, Kobayashi M, Pospisil M, et al. (1991) Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 173: 869-879.
26. Manetti R, Parronchi P, Giudizi MG, Piccinni MP, Maggi E, et al. (1993) Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells. J Exp Med 177: 1199-1204.
27. King DP, Jones PP, (1983) Induction of Ia and H-2 antigens on a macrophage cell line by immune interferon. J Immunol 131: 315-318.
28. Shafren DR, Au GG, Nguyen T, Newcombe NG, Haley ES, et al. (2004) Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, coxsackievirus a21. Clin Cancer Res 10: 53-60.
29. Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, et al. (2009) Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther 17: 158-170.
30. Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, et al. (2009) Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther 8: 141-151.
31. Worschech A, Haddad D, Stroncek DF, Wang E, Marincola FM, et al. (2009) The immunologic aspects of poxvirus oncolytic therapy. Cancer Immunol Immunother 58: 1355-1362.
32. Worschech A, Chen N, Yu YA, Zhang Q, Pos Z, et al. (2009) Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics 10: 301.
33. Cerwenka A, Baron JL, Lanier LL, (2001) Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci U S A 98: 11521-11526.
34. Karre K, Ljunggren HG, Piontek G, Kiessling R, (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319: 675-678.
35. Janeway CA Jr, (1989) Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 54 Pt 1: 1-13.
36. Matzinger P, (1994) Tolerance, danger, and the extended family. Annu Rev Immunol 12: 991-1045.
37. Matzinger P, (2002) The danger model: a renewed sense of self. Science 296: 301-305.
38. Unno Y, Shino Y, Kondo F, Igarashi N, Wang G, et al. (2005) Oncolytic viral therapy for cervical and ovarian cancer cells by Sindbis virus AR339 strain. Clin Cancer Res 11: 4553-4560.
39. Smyth MJ, Teng MW, Swann J, Kyparissoudis K, Godfrey DI, et al. (2006) CD4+CD25+ T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 176: 1582-1587.
40. Colombo MP, Trinchieri G, (2002) Interleukin-12 in anti-tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13: 155-168.
41. Ikeda H, Old LJ, Schreiber RD, (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13: 95-109.
42. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, et al. (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87: 581-586.
43. Elgert KD, Alleva DG, Mullins DW, (1998) Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64: 275-290.
44. Heitmeier MR, Scarim AL, Corbett JA, (1998) Double-stranded RNA-induced inducible nitric-oxide synthase expression and interleukin-1 release by murine macrophages requires NF-kappaB activation. J Biol Chem 273: 15301-15307.
45. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, et al. (2004) Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 5: 1260-1265.
46. Routes JM, Ryan S, Morris K, Takaki R, Cerwenka A, et al. (2005) Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J Exp Med 202: 1477-1482.
47. Ogbomo H, Michaelis M, Geiler J, van Rikxoort M, Muster T, et al. (2010) Tumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cells. Med Microbiol Immunol 199: 93-101.
48. Levine B, Huang Q, Isaacs JT, Reed JC, Griffin DE, et al. (1993) Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature 361: 739-742.
49. Venticinque L, Meruelo D, (2010) Sindbis viral vector induced apoptosis requires translational inhibition and signaling through Mcl-1 and Bak. Mol Cancer 9: 37.
50. Altomonte J, Wu L, Meseck M, Chen L, Ebert O, et al. (2009) Enhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cells. Cancer Gene Ther 16: 266-278.